| Drug Name |
Eculizumab |
| Drug ID |
BADD_D00742 |
| Description |
Eculizumab is a monoclonal antibody that targets complement protein C5.[L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.[L6919,A2245,A2246]
Eculizumab was granted FDA approval on 16 March 2007.[L6919] |
| Indications and Usage |
Eculizumab is indicated to treat paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy[L6919,A2246], and neuromyelitis optica spectrum disorder (NMOSD).[L6916] |
| Marketing Status |
approved; investigational |
| ATC Code |
L04AA25 |
| DrugBank ID |
DB01257
|
| KEGG ID |
D03940
|
| MeSH ID |
C481642
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D01RQV
|
| NDC Product Code |
69438-0001; 25682-001; 68225-042; 42098-0005 |
| UNII |
A3ULP0F556
|
| Synonyms |
eculizumab | 5G1.1 | H5G1.1VHC+H5G1.1VLC | H5G1.1 | H5G1-1 | H5G11 | Elizaria | Soliris | Alexion |
